Portco highlight: Journey Clinical

Subscribe or follow us
for latest news and invites
The future of mental healthcare looks different. Journey Clinical, Republic Ventures recent investment, is building that future by bringing psychedelic-assisted therapy into mainstream practice.

In portfolio since | Q3 2024 |
invested amount | $100,000 |
In a market projected to reach $93.8B by 2037, they're focusing on making these frontier treatments more accessible.
Journey Clinical CEO Jonathan Sabbagh gained relief from chronic burnout and PTSD through ketamine-assisted therapy. This personal experience led him and co-founder Myriam Barthes to create a scalable solution for millions living with treatment-resistant mental illness.
Since launching, they've attracted over 700 providers who have treated more than 1,000 patients across seven states.
Instead of the traditional clinic model, they empower independent practitioners to offer these treatments in their own practice. Their collaborative care model handles medical activities including eligibility, prescriptions, and treatment plans, while therapists focus on patient care.
Today, Journey Clinical is the #1 “psychedelic-assisted” psychotherapy platform with the largest network of licensed therapists in the US, enabling the delivery of high quality mental healthcare at scale with ketamine-assisted psychotherapy. With approximately 30% of people diagnosed with major depressive disorder resistant to conventional treatments, Journey Clinical is addressing this gap with a scalable solution.
Is psychedelic-assisted therapy the future of mental health care? Jonathan, co-founder of Journey Clinical believes so
Join our VC Files session with Journey Clinical CEO Jonathan Sabbagh tomorrow
Note holder exclusive offer from Journey Clinical
Discussion
More updates
Portco highlight: MetaEngine

Portfolio news: Cloudastructure, Passport, Janover and 23 more
